Prostate-specific antigen test 'does more harm than good'

Share :
Published: 29 Sep 2013
Views: 5231
Prof Mathieu Boniol - International Prevention Research Institute, Lyon, France

According to research presented by Professor Mathieu Boniol, at the 2013 European Cancer Congress (ECC 2013) men experience more harm than good from routine PSA screening.

Prostate cancer screening using the prostate-specific antigen (PSA) test is widely used in France despite a lack of evidence showing that it reduces cancer deaths.

Prof Boniol, Research Director at the International Prevention Research Institute (iPRI) and Professor at the Strathclyde Institute for Global Public Health at iPRI, Lyon, France, will tell the congress that the total harm men experience in terms of impotence and incontinence, and the side-effects from prostate cancer treatments, severely affects their quality of life, and should further discourage the use of PSA testing for prostate cancer screening.

Read more on ecancerNews


ecancer's filming at ECC has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.